HER2-positive breast cancer remains one of the most aggressive subtypes of the disease, and patients whose tumors metastasize or recur after standard treatment face a poor prognosis. The arrival of anti-HER2 antibody-drug conjugates has markedly improved outcomes in recent years. These engineered molecules pair an antibody that homes in on the HER2 protein with a potent cytotoxic payload, delivering chemotherapy directly to tumor cells while sparing healthy tissue. RC48 is a novel member of this class, and one of its most clinically intriguing features is that it exhibits antitumor activity not only against tumors with high HER2 expression but also against so-called HER2-low cancers, which were historically considered poor candidates for HER2-targeted therapy. Until now, however, the molecular details of how RC48 actually kills cancer cells, and what those deaths mean for the surrounding immune landscape, remained incompletely understood.

The research team set out to dissect that mechanism at the level of cell biology. Their experiments revealed that when RC48 engages HER2-expressing breast cancer cells, it sets off a cascade of oxidative damage: lipid reactive oxygen species accumulate in the cells’ membranes, pushing them toward ferroptosis. The team confirmed this using established experimental tools, including the C11-BODIPY fluorescence assay to measure lipid ROS, and showed that markers of the ferroptotic pathway, such as the proteins SLC7A11 and GPX4, changed in ways consistent with this form of cell death. Importantly, the ferroptotic and apoptotic programs ran in parallel rather than in sequence. When the researchers blocked ferroptosis with the inhibitor ferrostatin-1, or blocked apoptosis with QVD-O-Ph, they could dissect the relative contributions of each pathway to RC48’s killing effect, and necrostatin-1, an inhibitor of necroptosis, did not rescue cell viability, ruling out that alternative death route as a major player.

What elevates the finding beyond a simple cell-death study is the immunological consequence of that ferroptosis. As tumor cells succumb, they release a characteristic cocktail of damage-associated molecular patterns, including adenosine triphosphate, high-mobility group box 1 protein, and surface-exposed calreticulin. These three signals are the classic hallmarks of immunogenic cell death, a special category of cell demise that the immune system recognizes as dangerous rather than silent. In effect, the dying tumor cells hand the immune system a set of molecular breadcrumbs. The study showed that these emitted signals promote the maturation of dendritic cells, the sentinels that collect debris from dead cells and present fragments of it to T cells, thereby priming an adaptive immune response targeted at the tumor itself.

That priming translated into measurable changes inside the tumor microenvironment. The researchers documented increased infiltration of CD8-positive T cells into tumors following RC48 treatment, along with enhanced cytotoxic function of those cells. Flow cytometric analysis revealed higher levels of granzyme B, interferon gamma, and tumor necrosis factor alpha, the molecular weapons and signaling molecules that CD8-positive T cells deploy when they recognize and attack their targets. In co-culture experiments, CD8-positive T cells exposed to RC48-treated tumor cells showed markedly elevated granzyme B expression, and this effect was abolished when ferroptosis was blocked with ferrostatin-1, directly linking the cell-death program to the immune activation. The team also observed that RC48 treatment upregulated PD-L1 on the surface of surviving tumor cells, an adaptive escape response that tumors use to suppress attacking T cells.

That upregulation of PD-L1 pointed the investigators toward a rational combination strategy. If RC48 both kills tumor cells immunogenically and simultaneously induces the very checkpoint molecule that tumors use to evade immune attack, then pairing the drug with an antibody that blocks PD-L1 should unleash the full potential of the activated T cell response. In vivo mouse models bore this out. The researchers used engineered tumor models, including hHER2-4T1 mice bearing tumors that express human HER2, to evaluate RC48 both as a monotherapy and in combination with anti-PD-L1 therapy. The results confirmed the efficacy and safety of RC48 in both settings, with the combination offering a way to prevent the tumor from slamming the immune brakes just as the drug had floored the accelerator.

The specificity of the mechanism adds an important layer of clinical relevance. In HER2-negative cell lines, including E0771 and 4T1, RC48 did not induce ferroptosis, did not trigger the release of ATP or HMGB1, and did not produce the other signatures of immunogenic cell death. This dependence on HER2 expression means the immunostimulatory effects of the drug are concentrated where the drug is delivered, in tumors carrying the target antigen. The researchers also verified that HER2 expression itself was not significantly altered by RC48 treatment in the tumor tissues of the mouse models, suggesting the drug does not inadvertently select for antigen-loss variants during the treatment window examined. Supporting epidemiological analyses using the GEPIA2.0 and TIMER2.0 databases showed that ferroptosis-related gene signatures, including HMOX1 and ACSL4, correlate with the infiltration of effector T cells, Th1-like cells, and dendritic cells in breast cancer, lending population-level plausibility to the mechanistic story.

The study arrives at a moment when the field is actively rethinking what antibody-drug conjugates can do. These agents were originally conceived as targeted chemotherapy delivery vehicles, but accumulating evidence suggests that the way they kill cells matters as much as how many cells they kill. Immunogenic cell death, with its release of damage signals and recruitment of dendritic cells, can convert a tumor from an immunologically cold site into a hot one, primed for checkpoint blockade. By delineating a ferroptosis-to-immunogenic-cell-death-to-immunity axis for RC48, the Shanghai and Beijing team has provided a mechanistic rationale for combining this ADC with immune checkpoint inhibitors, a strategy their in vivo data already support. The findings also help explain why RC48 shows activity in HER2-low tumors, since the drug’s cytotoxic and immune-activating effects can operate wherever the conjugate can dock, even at lower antigen density.

Several caveats temper the immediate clinical implications. The mechanistic work rests heavily on cell lines and mouse models, including the hHER2-4T1 system, and the authors note that the article was shared early as a peer-reviewed, citable version of record that remains subject to further editorial processing. Translating the ferroptosis-ICD-immune axis into patient benefit will require clinical trials that test RC48 alone and in combination with PD-L1 blockade in patients with HER2-expressing breast cancer, with careful attention to the safety of combining a cytotoxic payload with immunotherapy. Nevertheless, the study was funded by the National Natural Science Foundation of China and Shanghai municipal research programs, and the corresponding authors, Chenwei Yuan, Jinsong Lu, and Wenjin Yin, argue that the data collectively support RC48’s continued clinical development both as a monotherapy and in combination regimens.

For patients and clinicians watching the antibody-drug conjugate field, the message is that RC48 may be more than a precision-guided toxin. By killing tumor cells through ferroptosis and thereby converting their deaths into an immune signal, the drug appears to engineer its own follow-up attack, mobilizing CD8-positive T cells that can hunt down surviving malignant cells. The demonstration that this process depends on HER2 expression, that it can be blocked by ferroptosis inhibitors, and that it pairs logically with checkpoint blockade gives researchers a coherent framework for designing the next generation of trials. If the ferroptosis-immunity axis holds up in human studies, RC48 and drugs like it could become foundational components of combination therapy for HER2-expressing breast cancer, turning a targeted chemotherapy agent into a personalized in situ cancer vaccine of sorts.

Subject of Research: Mechanism of the anti-HER2 antibody-drug conjugate disitamab vedotin in inducing ferroptosis and antitumor immunity in HER2-expressing breast cancer

Article Title: Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer

Article References: Zhao, Y., Yuan, C., Wu, Q., Wu, Z., Peng, J., Lin, Y., Lu, J., & Yin, W. (2026). Disitamab vedotin triggers ferroptosis to activate CD8+ T-cell antitumor immunity in HER2-expressing breast cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03836-x

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03836-x

Keywords: disitamab vedotin, RC48, HER2-positive breast cancer, antibody-drug conjugate, ferroptosis, immunogenic cell death, CD8-positive T cells, damage-associated molecular patterns, PD-L1, dendritic cells, lipid reactive oxygen species, tumor microenvironment

The clinical problem the review addresses is stark. Immune checkpoint inhibitors, the drugs that have revolutionized treatment of many advanced cancers, work spectacularly well in only a small subset of colorectal cancer patients. Tumors classified as microsatellite instability-high, which carry abundant mutations and are therefore highly visible to the immune system, respond robustly to pembrolizumab and similar agents, with five-year follow-up from the randomized phase III KEYNOTE-177 study confirming durable benefit over chemotherapy. But the vast majority of metastatic colorectal cancers are microsatellite-stable, meaning their mutation burden is low and their immune landscape is cold: few T cells infiltrate the tumor, and suppressive cells and signaling molecules actively keep the immune system at bay. For these patients, checkpoint blockade alone offers little, and the search for ways to convert cold tumors into hot ones has become one of the field’s most urgent priorities.

The authors frame their solution around what they call the tumor-immune-soil nexus, a conceptual model in which the tumor, the immune system, and the surrounding microenvironment form an interdependent ecosystem. Within this framework, Traditional Chinese Medicine formulas are proposed to function as formula-defined ecological conditioners, multi-target systems that simultaneously adjust several parameters of the ecosystem rather than hitting a single molecular switch. The blueprint rests on three actionable pillars: remodeling the gut microbiome to restore immune-supportive bacterial communities and metabolic flux, reprogramming the myeloid compartment away from immunosuppressive states, and inducing immunogenic cell death in tumor cells to generate the danger signals needed to ignite an immune response. Each pillar is grounded in a growing body of preclinical and early clinical evidence.

The first pillar, microbiome remodeling, is perhaps the most provocative. The gut harbors trillions of bacteria that shape systemic immunity, and disruption of this community has been linked to colorectal cancer development and to poor responses to immunotherapy. Several classical herbal formulas have now been shown in experimental systems to reshape gut microbial composition. Gegen Qinlian decoction, for example, was reported to enhance the effect of PD-1 blockade in microsatellite-stable colorectal cancer models by remodeling both the gut microbiota and the tumor microenvironment. Huang-Lian-Jie-Du decoction enhanced the efficacy of capecitabine and oxaliplatin through the bacterium Akkermansia muciniphila and CD8-positive T cells, while Shenling Baizhu powder has been implicated in potentiating immunotherapy response through gut microbial remodeling and fatty acid metabolism modulation. Herbal compounds can also repair the intestinal barrier, whose breakdown allows bacterial products and even live bacteria to disseminate and promote metastasis, particularly to the liver.

Metabolism provides the mechanistic bridge between microbes and immune cells. Bacterial metabolites such as short-chain fatty acids and bile acids profoundly influence T cell differentiation, including the balance between inflammatory Th17 cells and suppressive regulatory T cells. Secondary bile acids produced by gut bacteria have been linked to Western diet-associated colorectal cancer and to liver metastasis through altered neutrophil recruitment. The review argues that by steering microbial metabolism, herbal formulas could shift these metabolite pools toward configurations that favor anti-tumor immunity. The authors also invoke the classical concept of the Gan Pi axis, a traditional framework linking liver and spleen physiology, and propose translating it into modern immunometabolism, suggesting that ancient syndrome categories may map onto measurable metabolic and immune states that can be targeted and monitored.

The second pillar targets the myeloid compartment, the army of innate immune cells that in colorectal cancer too often works for the tumor rather than against it. Tumor-associated macrophages polarized toward the M2 phenotype and myeloid-derived suppressor cells both suppress cytotoxic T cells and correlate with poor outcomes. TGF-beta signaling builds what researchers have described as a dual immune barrier by impairing T cell recruitment and instructing immunosuppressive macrophages, while molecules such as MNDA promote immunosuppression by facilitating infiltration of polymorphonuclear myeloid-derived suppressor cells. Here again, herbal pharmacology offers candidate tools: Astragalus polysaccharide has been shown to induce macrophage polarization toward the pro-inflammatory M1 state via Notch signaling, curcumin has been reported to inhibit and redifferentiate myeloid-derived suppressor cells, and artesunate modulates macrophage inflammatory signaling through the TLR4 pathway. Senescent fibroblasts, which drive T cell dysfunction through CD36-mediated lipid transfer, represent another stromal target within this pillar.

The third pillar addresses the fundamental requirement that the immune system must first perceive cancer as a threat. Immunogenic cell death is a specialized form of tumor cell demise that exposes calreticulin on the cell surface and releases danger signals, allowing dendritic cells to capture tumor antigens and prime T cell responses. Several compounds derived from Chinese herbs have been shown to induce this process: cantharidin-loaded nanomedicines triggered immunogenic cell death to enhance PD-1 blockade in preclinical models, and triptolide induced immunogenic cell death through endoplasmic reticulum stress and redox modulation. The review also highlights the STING pathway, a DNA-sensing circuit that is frequently epigenetically silenced in colorectal carcinoma, constraining DNA damage responses and enabling immune escape. Reactivating such danger-sensing machinery, the authors argue, is a prerequisite for converting the immune desert of microsatellite-stable tumors into productive anti-tumor immunity.

The authors are notably candid about the weaknesses of the existing evidence base, and this honesty distinguishes the review from more promotional treatments of the topic. A significant portion of the human data on Traditional Chinese Medicine in colorectal cancer remains observational, cross-sectional, or case-control in design, which limits causal inference and makes it impossible to reconstruct the long-term temporal sequence linking immune and microbiome dynamics to cancer progression or treatment response. Herb-drug interactions add a further layer of complexity: compounds such as baicalein and baicalin can alter the activity of drug-metabolizing enzymes like CYP3A4 and the transporter p-glycoprotein, changing the pharmacokinetics of co-administered drugs, a lesson underscored by the classic demonstration that St. John’s wort accelerates irinotecan metabolism. Without chemical standardization of formulas and careful pharmacokinetic monitoring, combination strategies risk being confounded or even dangerous.

To move the field forward, the review proposes a concrete methodological agenda. Future trials should evaluate standardized, chemically characterized formulas within adaptive platform designs that incorporate biomarker-driven endpoints, an approach aligned with the FDA’s botanical drug development guidance and with the emerging infrastructure of precision oncology trials. Validation tools should include spatial transcriptomics to map whether candidate formulas genuinely convert cold tumor regions into immune-inflamed ones, and microbiome-humanized mouse models that allow patient-derived microbial communities to be tested in controlled experiments. Network pharmacology, artificial intelligence-driven synergy prediction, and multi-omics integration are proposed as engines for identifying which combinations of herbal constituents produce the desired ecological shifts, while organoid platforms derived from patients could screen for resistance mechanisms before trials begin.

If the blueprint succeeds, the implications would extend well beyond colorectal cancer, offering a template for rationally integrating multi-component natural products with immunotherapy across tumor types. The vision is not herbal medicine as an alternative to mainstream oncology but as a priming agent, one that conditions the tumor ecosystem so that checkpoint inhibitors can work in the patients who currently derive no benefit from them. Whether classical formulas can survive the rigor of standardized chemistry, adaptive trials, and mechanistic validation remains an open question, but the review makes a compelling case that the answer is worth pursuing with the full arsenal of modern cancer science.

Subject of Research: Integrating Traditional Chinese Medicine with immune checkpoint inhibitors to convert immunotherapy-resistant microsatellite-stable metastatic colorectal cancer into an immune-responsive state

Article Title: Beyond the barrier: Engineering the tumor-immune-soil nexus–a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer

Article References: Beyond the barrier: Engineering the tumor-immune-soil nexus–a mechanistic blueprint for integrating Traditional Chinese Medicine with immunotherapy in metastatic colorectal cancer. (n.d.). https://doi.org/10.1007/s12032-026-03397-1

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03397-1

Keywords: metastatic colorectal cancer, Traditional Chinese Medicine, immune checkpoint inhibitors, gut microbiome, tumor microenvironment, immunotherapy resistance, microsatellite stability, immunogenic cell death, myeloid-derived suppressor cells, macrophage polarization, gut barrier, spatial transcriptomics

The review, authored by Luqi Ying, Zhiwei Zhang, and Luwen Zhao, systematically examines the mechanistic rationale, accumulating clinical evidence, and future directions of combining immune checkpoint inhibitors (ICIs) with poly (ADP-ribose) polymerase inhibitors (PARPis) in ovarian cancer. Its central thesis is that these two drug classes, while developed along entirely separate scientific lineages, attack the disease through distinct yet deeply complementary mechanisms, and that their synergy may be particularly valuable precisely where conventional treatment fails most often: in the setting of acquired platinum resistance.

To appreciate why the combination makes biological sense, it helps to understand why platinum resistance develops in the first place. The authors describe a multifaceted resistance architecture. Tumor cells can ramp up their DNA damage repair machinery, patching the cross-linking lesions that platinum drugs inflict before those lesions become lethal. They can increase drug efflux, pumping chemotherapy out of the cell faster than it accumulates. Perhaps most insidiously, they remodel the tumor immune microenvironment, building an immunosuppressive fortress that shields the malignancy from immune surveillance. Each of these escape routes on its own can doom a single-agent therapy; together, they explain why recurrent platinum-resistant ovarian cancer has proven so stubbornly difficult to treat.

PARP inhibitors were originally designed to exploit a different vulnerability. Poly (ADP-ribose) polymerase is a key enzyme in the repair of single-strand DNA breaks. When PARPis block this enzyme, the unrepaired breaks collapse replication forks and convert into double-strand breaks, which are catastrophic for cells that also lack functional homologous recombination repair, the hallmark of tumors with BRCA mutations or homologous recombination deficiency (HRD). This synthetic lethality principle has already transformed maintenance therapy for ovarian cancer. But the review highlights an emerging second dimension of PARPi activity: beyond directly crippling DNA repair, these drugs fundamentally change how tumors look to the immune system.

The mechanistic centerpiece of the review is the cGAS–STING pathway. When PARPis induce DNA damage, fragments of DNA escape the nucleus and accumulate in the cytoplasm, where the enzyme cyclic GMP-AMP synthase (cGAS) detects them. cGAS activation triggers the stimulator of interferon genes (STING), which sets off a signaling cascade culminating in the production of type I interferons. These interferons act as a molecular alarm, recruiting and activating antigen-presenting cells such as dendritic cells, which then display tumor antigens to cytotoxic T cells. In parallel, PARPi-induced DNA damage can provoke immunogenic cell death, a form of tumor cell demise that releases damage-associated molecular patterns, including calreticulin and high mobility group box 1, which further stoke immune activation. The net effect, as the authors describe it, is the conversion of immunologically cold tumors into hot ones, transforming tumors that were previously invisible to the immune system into inflamed targets teeming with immune activity.

This is where immune checkpoint inhibitors enter the picture. Drugs targeting PD-1 and its ligand PD-L1 release the molecular brakes that tumors place on T cells, but they work only if T cells are present and engaged in the first place. In cold, immunosuppressive tumors, checkpoint blockade alone often achieves little. PARPis solve this problem by generating the very inflammatory context that ICIs require. The combination, in principle, simultaneously ignites the immune response and removes the brakes on it, a logic that the review argues is especially potent against the immunosuppressive milieu that accompanies platinum resistance.

The clinical evidence supporting this paradigm spans multiple disease settings. In the first-line maintenance setting, the DUO-O trial demonstrated that a triple combination of the PD-L1 inhibitor durvalumab, the PARPi olaparib, and bevacizumab significantly extended progression-free survival in patients whose tumors were HRD-positive. This result is notable because it embeds the ICI–PARPi pairing within a broader anti-angiogenic backbone, suggesting that the strategy can deliver measurable benefit even in newly diagnosed disease. In the platinum-resistant recurrent setting, the TOPACIO/KEYNOTE-162 study of pembrolizumab combined with niraparib indicated that response to the combination therapy correlated with DNA repair status, including HRD and BRCA mutation status. Together, these findings suggest that the combination is not a blunt instrument but one whose activity tracks with definable tumor biology.

That last point, biomarker-driven patient selection, emerges as the decisive theme of the review’s forward-looking section. The authors argue that realizing the full potential of personalized treatment in ovarian cancer will require integrating HRD status, features of the immune microenvironment, and emerging predictive factors into a coherent selection framework. Not every patient will benefit from the combination, and the ability to identify responders in advance, through genomic profiling of DNA damage repair defects, assessment of PD-L1 expression or immune infiltration, and potentially novel predictive markers, will determine whether the paradigm fulfills its promise or dissipates into one-size-fits-all disappointment. The review’s extensive abbreviation list, spanning DNA damage response pathways from base excision repair to Fanconi anemia genes, hints at the breadth of molecular features that may eventually inform patient stratification.

Equally important is the unresolved question of resistance. Just as tumors evolved escape routes from platinum chemotherapy, they can be expected to develop mechanisms that blunt the ICI–PARPi combination: loss of antigen presentation, upregulation of alternative checkpoints such as LAG-3 and TIM-3, adaptations in interferon signaling through the JAK–STAT pathway, and further remodeling of the microenvironment by factors such as TGF-β. The authors emphasize that deeper investigation into these resistance mechanisms will be essential, both to anticipate relapse and to design rational next-generation combinations that stack additional agents against parallel escape pathways.

For a disease that has long been defined by grim arithmetic, the convergence of DNA damage biology and cancer immunology offers something genuinely new. The review does not claim victory; it maps a paradigm still under construction, with pivotal trials completed in some settings and open questions in others. But its synthesis makes a compelling case that the future of recurrent platinum-resistant ovarian cancer lies not in any single drug, but in intelligently combined ones, guided by biomarkers that match each patient’s tumor to the therapy most likely to work. If the field can deliver on that vision, one of oncology’s most feared treatment ceilings may finally begin to crack.

Subject of Research: Combination of immune checkpoint inhibitors and PARP inhibitors for recurrent platinum-resistant ovarian cancer

Article Title: A new paradigm for treating recurrent platinum-resistant ovarian cancer: synergistic mechanisms, clinical evidence, and future directions of immune checkpoint inhibitors combined with PARP inhibitors

Article References: Ying, L., Zhang, Z., & Zhao, L. (2026). A new paradigm for treating recurrent platinum-resistant ovarian cancer: synergistic mechanisms, clinical evidence, and future directions of immune checkpoint inhibitors combined with PARP inhibitors. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02270-z

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02270-z

Keywords: ovarian cancer, immune checkpoint inhibitors, PARP inhibitors, platinum resistance, cGAS-STING pathway, homologous recombination deficiency, immunogenic cell death, DUO-O trial, TOPACIO trial, biomarkers, combination therapy, tumor microenvironment

Pancreatic neuroendocrine tumors are an uncommon but stubborn group of malignancies. Unlike the more familiar pancreatic adenocarcinomas, they often express high levels of somatostatin receptors on their surface, a molecular feature that has made them eligible for peptide receptor radionuclide therapy. In this approach, a hormone-like peptide called DOTATATE binds to those receptors and delivers a radioactive payload, lutetium-177, directly into tumor cells. The beta radiation released by lutetium-177 travels only a few millimeters in tissue, damaging DNA and triggering cell death in tumor cells while largely sparing surrounding healthy tissue. Clinical trials have shown meaningful benefit, but responses are rarely complete, and resistance eventually develops in many patients.

Sunitinib, meanwhile, is a multitargeted oral kinase inhibitor that blocks several receptors involved in tumor angiogenesis, including vascular endothelial growth factor receptors and platelet-derived growth factor receptors. By starving tumors of their blood supply and directly inhibiting survival signaling within tumor cells, sunitinib has extended progression-free survival in patients with advanced pancreatic neuroendocrine tumors. Clinicians have observed that combining sunitinib with 177Lu-DOTATATE appears to produce deeper and more lasting responses, but the biological basis of this synergy remained poorly defined.

The new research set out to test a specific hypothesis: that the combination does more than simply add two cytotoxic effects. Immunogenic cell death is a specialized form of cell demise in which dying tumor cells release or expose a characteristic set of signals, often called damage-associated molecular patterns. These include calreticulin translocated to the cell surface, secretion of ATP, release of high-mobility group box 1 protein, and presentation of tumor antigens on major histocompatibility complex molecules. Together, these signals attract and activate dendritic cells, which then carry tumor antigens to lymph nodes and prime cytotoxic T lymphocytes capable of hunting down residual cancer cells throughout the body.

Using preclinical models of pancreatic neuroendocrine tumors, the investigators showed that each therapy alone induced only limited immunogenic signaling. Sunitinib treatment produced vascular changes and some direct tumor cell stress, while 177Lu-DOTATATE delivered DNA-damaging radiation that killed a fraction of receptor-expressing cells. Neither monotherapy reliably provoked the full repertoire of immunogenic death markers. When the two were combined, however, the picture changed dramatically. Tumor cells exposed to both agents displayed significantly increased surface calreticulin, elevated ATP secretion, and heightened release of high-mobility group box 1 protein into the tumor microenvironment.

The mechanistic studies went further. The researchers found that sunitinib pretreatment increased the expression of entosis-related and autophagy pathways in tumor cells, processes that are known to be required for the calreticulin exposure that defines immunogenic cell death. At the same time, radiation from lutetium-177 inflicted the DNA damage and endoplasmic reticulum stress that serve as the danger signals alerting the immune system. In effect, the kinase inhibitor appeared to prepare tumor cells for a form of death that the radiopharmaceutical then converted into an immunological alarm, transforming what would otherwise be a quiet, non-inflammatory demise into a stimulus capable of recruiting dendritic cells and activating T cells.

The immune consequences were visible within the tumors themselves. Combination-treated tumors showed increased infiltration by CD8-positive cytotoxic T lymphocytes, higher ratios of effector T cells to immunosuppressive regulatory T cells, and evidence of dendritic cell activation. Interferon-gamma signatures were upregulated, indicating that T cells within the tumor microenvironment had been functionally engaged rather than merely present. The researchers also documented reductions in myeloid-derived suppressor cells and markers of tumor-associated immunosuppression, suggesting that the combination remodels the tumor microenvironment in a direction that favors immune attack.

Perhaps the most striking evidence came from experiments in which the researchers depleted specific immune cell populations or blocked key signaling pathways. When CD8-positive T cells were removed, the survival advantage and tumor control conferred by the combination largely disappeared, demonstrating that the adaptive immune response was not an incidental byproduct but a required component of the therapeutic synergy. Similarly, blocking the recognition of damage-associated molecular patterns abrogated the dendritic cell activation and downstream T cell priming. These findings establish the combination as a bona fide inducer of a vaccination-like effect arising from within the tumor itself.

The implications for clinical practice are considerable. Immunogenic cell death has become one of the central concepts in the rational design of combinations with immune checkpoint inhibitors, since checkpoint blockade works best when antitumor T cells have already been primed. The new findings provide a mechanistic rationale for testing 177Lu-DOTATATE and sunitinib together with agents such as PD-1 or PD-L1 inhibitors in pancreatic neuroendocrine tumors, a disease in which immunotherapy alone has so far shown limited activity. Ongoing and planned clinical trials may now incorporate biomarkers of immunogenic cell death, such as serum high-mobility group box 1 levels or tumor calreticulin staining, as pharmacodynamic readouts of whether the combination is successfully igniting antitumor immunity in individual patients.

The study also carries broader lessons for nuclear medicine. Radiopharmaceuticals have often been viewed as precision cytotoxic tools whose benefits are confined to their radioactive range. Work of this kind reinforces an emerging view that targeted radionuclide therapy can function as an in situ tumor vaccine, and that pairing it with agents that modulate tumor cell death pathways, vascular biology, or immune checkpoints can convert localized radiation into systemic immunological control. For patients with pancreatic neuroendocrine tumors, whose treatment options narrow sharply after somatostatin analogs, everolimus, sunitinib, and 177Lu-DOTATATE have been exhausted, the prospect of a combination that teaches the immune system to finish what the drugs begin offers a genuinely new therapeutic direction grounded in a mechanism that can now be measured, monitored, and deliberately enhanced.

Subject of Research: Mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy via immunogenic cell death in pancreatic neuroendocrine tumors

Article Title: Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors

Article References: Essler, M., Veit, N., Müller, A., Marinova, M., & Kreppel, B. (2026). Immunogenic cell death as a mechanism of synergy between sunitinib and 177Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors. Cell Death Discovery, 12(1), Article 379. https://doi.org/10.1038/s41420-026-03344-z

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03344-z

Keywords: immunogenic cell death, sunitinib, 177Lu-DOTATATE, peptide receptor radionuclide therapy, pancreatic neuroendocrine tumors, calreticulin, damage-associated molecular patterns, dendritic cells, CD8 T cells, tumor microenvironment, radiopharmaceuticals, immunotherapy synergy

The review, conducted by researchers at Shiraz University of Medical Sciences, Tehran University of Medical Sciences and University College London, followed the PRISMA 2020 guidelines and searched PubMed, Scopus, Web of Science and Embase for studies published up to September 2025. The team’s protocol was prospectively registered in the PROSPERO database. From the initial search, twenty-four preclinical studies met the inclusion criteria: animal models in which investigators assessed distant tumor regression or systemic immune activation following PDT, whether delivered alone or in combination with other therapies.

The findings were strikingly consistent. Across the included studies, PDT reliably produced local tumor regression and activated the immune system, with the molecular fingerprints of immunogenic cell death clearly visible. Dying tumor cells released damage-associated molecular patterns, exposed calreticulin on their surfaces, and recruited cytotoxic CD8-positive T lymphocytes into the tumor microenvironment. These are the same hallmarks that immunologists look for when a cell death event is capable of training the adaptive immune system to recognize and attack cancer, rather than simply clearing debris.

The abscopal effect itself, named from ‘ab’ meaning away and ‘scopal’ meaning target, has historically been a rare and unpredictable curiosity in radiation oncology. When it occurs, a localized treatment appears to prime immune cells that then travel through the circulation and attack tumors that were never irradiated. For decades, clinicians reported it only sporadically, and its rarity made it difficult to study. The new review suggests that PDT may offer a more controllable way to induce this systemic response, because the therapy’s oxidative burst can be tuned by adjusting drug dose, light intensity, timing and photosensitizer chemistry.

Crucially, the strongest abscopal responses emerged when PDT was paired with immune checkpoint blockade, specifically antibodies targeting programmed cell death protein-1, or PD-1, and its ligand PD-L1. Checkpoint inhibitors release the molecular brakes that tumors place on T cells, and the review’s authors found that combining them with PDT’s immune-priming effect produced clear distant tumor regression in several animal studies. Adjuvants, substances that boost immune signaling, also amplified the systemic response when co-administered with the light treatment. This synergy makes mechanistic sense: PDT floods the tumor with antigens and danger signals, while checkpoint blockade ensures the newly activated T cells are not silenced as they circulate.

The systemic nature of the immune activation was confirmed at the molecular level. Multiple studies reported upregulation of key inflammatory cytokines, including interleukin-6, interferon-gamma and tumor necrosis factor-alpha, in the circulation of treated animals. These signaling molecules are characteristic of a robust, body-wide immune response rather than a purely local inflammatory reaction. Interferon-gamma in particular is central to antitumor immunity, enhancing antigen presentation and directly inhibiting tumor cell proliferation, while tumor necrosis factor-alpha contributes to vascular disruption within tumors and supports cytotoxic lymphocyte function.

What distinguishes PDT from radiotherapy, its closest conceptual rival for abscopal induction, is the nature of the cell death it provokes. Reactive oxygen species generated by the photosensitizer can trigger immunogenic apoptosis and necrosis while preserving tumor antigen integrity, and PDT can also damage tumor vasculature and reprogram the immunosuppressive tumor microenvironment. The review notes that immune reprogramming, the shift of a tumor from a cold, T-cell-excluded state to a hot, inflamed state, appears to be a key mechanism by which PDT converts a local treatment into a systemic one. By depleting suppressive myeloid cells and regulatory T cells and promoting dendritic cell maturation, PDT can create the conditions under which newly primed T cells can function effectively.

The authors are careful to frame their conclusions as preclinical, with early clinical studies offering preliminary support but not definitive proof. Animal models of cancer frequently overstate immune effects that later fail to translate into human trials, and the twenty-four studies included in the review varied in photosensitizer, tumor model, light dosing and combination regimens, making direct comparison difficult. The review nonetheless argues that the consistency of the immune activation signals across models, and the reproducibility of abscopal responses when PDT is combined with checkpoint blockade, justify moving the field toward carefully designed clinical evaluation. Optimizing treatment parameters, the authors suggest, may allow PDT to evolve from a local, cytotoxic treatment into a genuine systemic cancer immunotherapy.

The implications for patients with metastatic disease are considerable. If a clinician could illuminate a single accessible lesion and thereby vaccinate the patient’s immune system against their own tumor, the strategy could complement existing immunotherapies rather than replace them. Combination trials pairing PDT with PD-1 or PD-L1 inhibitors are the most obvious next step, and the review’s systematic synthesis of preclinical evidence provides a roadmap for which parameters, photosensitizers and adjuvant strategies appear most promising. Questions remain about the durability of the induced immunity, the risk of immune-related adverse events, and whether human tumors, which are more heterogeneous than laboratory models, will respond as predictably.

For now, the review stands as the most comprehensive preclinical assessment to date of PDT’s ability to reach beyond the beam of light that delivers it. It documents a therapy long thought of as surgically precise quietly revealing a second identity: an immune catalyst capable of sending signals far beyond the treated site. As the authors conclude, with optimized parameters and rational combinations with immunotherapy, photodynamic therapy may develop from a local cytotoxic tool into a systemic weapon against cancer, one that turns a single illuminated tumor into the trigger for a body-wide immune campaign.

Subject of Research: Systematic review of preclinical evidence that photodynamic therapy induces immunogenic cell death and abscopal, systemic antitumor immune responses

Article Title: Immunogenic and systemic antitumor responses induced by photodynamic therapy: a systematic review of the abscopal effect

Article References: Faghani-Eskandarkolaei, P., Zareei-khooshab, V., Mansouri-Bidekani, R., Heli, H., Abdollahi, M., Haghighi, H., Zahraie, N., & Sattarahmady, N. (2026). Immunogenic and systemic antitumor responses induced by photodynamic therapy: a systematic review of the abscopal effect. Cancer Cell International. https://doi.org/10.1186/s12935-026-04455-4

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04455-4

Keywords: photodynamic therapy, abscopal effect, immunogenic cell death, reactive oxygen species, immune checkpoint blockade, CD8-positive T lymphocytes, calreticulin, damage-associated molecular patterns, cytokines, tumor microenvironment, cancer immunotherapy, metastatic cancer

NINJ1 first attracted attention in immunology circles for its unusual structural capabilities. When activated during lytic forms of cell death, including pyroptosis and necroptosis, NINJ1 proteins assemble into filamentous oligomers along the cell surface. Using a distinctive helical-alpha helix interaction motif, these proteins pack side by side into a growing chain that ultimately seals into a ring, mechanically prying the membrane apart. Cryo-electron microscopy studies have revealed how individual subunits engage one another and how small molecules can disrupt this assembly, offering researchers their first mechanistic picture of how a cell actively tears itself open. The result is the release of intracellular contents, ranging from damage-associated molecular patterns such as HMGB1 and ATP to mature inflammatory cytokines, into the extracellular space, where they act as powerful alarm signals for the immune system.

The scope of NINJ1’s involvement, however, extends well beyond pyroptosis. The review systematically traces the protein’s fingerprints across the major lytic death pathways. In necroptosis, driven by the MLKL kinase downstream of TNF receptor signaling, NINJ1 determines whether membrane breakdown is complete and whether cellular contents spill out to provoke inflammation. In ferroptosis, the iron-dependent lipid peroxidation-driven death implicated in tissue injury and therapy resistance, NINJ1 likewise mediates the terminal rupture. Even in secondary necrosis, the late-stage membrane collapse that follows otherwise non-lytic apoptosis, NINJ1 appears to govern the release of material from cells that initially died quietly. In PANoptosis, a recently described inflammatory death modality that integrates features of pyroptosis, apoptosis, and necroptosis, NINJ1 sits at the convergence point where intracellular alarm systems are converted into extracellular immunological signals.

This role in content release has profound consequences for inflammation. The magnitude and character of the immune response triggered by a dying cell depend substantially on what escapes through the ruptured membrane and in what quantity. By controlling plasma membrane rupture, NINJ1 effectively acts as a rheostat for the inflammatory tone of a tissue. In settings of acute infection, this can be protective, amplifying the recruitment of neutrophils and macrophages to sites of microbial invasion. In chronic disease, however, the same mechanism can sustain a self-perpetuating cycle of damage and inflammation, a dynamic well recognized in sepsis, ischemia-reperfusion injury, and inflammatory bowel disease. Pharmacological interference with NINJ1 oligomerization, informed by recent structural work, is now being explored as a strategy to dampen pathological inflammation without abolishing cell death itself.

It is in cancer, though, that NINJ1’s story becomes genuinely double-edged, and it is this duality that forms the conceptual core of the review. On one side of the ledger, NINJ1 can function as a tumor suppressor. When cancer cells undergo immunogenic cell death, the release of tumor antigens and danger signals through NINJ1-mediated rupture can provoke a robust adaptive immune response, generating dendritic cell activation, T cell priming, and durable anti-tumor immunity. In this context, a cell that dies loudly and publicly is a cell that teaches the immune system to recognize and eliminate its malignant relatives. Chemotherapy and radiotherapy regimens that induce immunogenic death may therefore depend partly on intact NINJ1 function for their full therapeutic benefit, raising the possibility that NINJ1 status could serve as a biomarker for treatment response.

On the other side of the ledger, the review documents compelling evidence that NINJ1 can act as a pro-tumor factor. In the tumor microenvironment, chronic and poorly resolved inflammatory death can fuel the very processes that cancers exploit to progress. Persistent release of inflammatory mediators promotes the recruitment of immunosuppressive myeloid cells, skews macrophages toward tumor-promoting phenotypes, and creates a milieu favorable to angiogenesis and invasion. Moreover, tumor cells with altered NINJ1 expression may evade immune recognition or reshape their surroundings in ways that facilitate metastasis. The review also highlights the p53–NINJ1–xCT axis as an instructive example of context-dependent regulation, in which the tumor suppressor p53 influences NINJ1 expression and, through it, the activity of the cystine-glutamate antiporter xCT, linking cell death execution directly to metabolic adaptation and ferroptosis sensitivity in cancer cells.

Immune cell trafficking adds yet another layer to NINJ1’s expanding portfolio. The protein takes its name from the Japanese word ninjin, meaning nerve, reflecting its original identification in neuronal adhesion, and earlier work established roles for ninjurins in leukocyte migration and adhesion. In tumors, immune cell infiltration is a critical determinant of prognosis and immunotherapy success, and NINJ1-dependent mechanisms appear to influence how immune cells move through and interact with the tumor stroma. The review suggests that dissecting these functions could reveal why some tumors mount vigorous immune infiltrates while others remain immunologically cold, a distinction with direct implications for checkpoint inhibitor therapy.

From a translational standpoint, the authors frame NINJ1 as a molecule whose therapeutic manipulation must be exquisitely context-aware. Blocking NINJ1 might relieve destructive inflammation in sepsis or autoinflammatory disease, yet the same intervention could blunt the immunogenic death signals that make certain anti-cancer treatments work. Conversely, enhancing NINJ1-mediated rupture within tumors might convert immunologically silent lesions into inflamed, immune-visible targets, but it risks amplifying the chronic inflammatory circuits that drive tumor progression in other settings. The dual role means that NINJ1-directed therapies will likely require careful patient selection, perhaps guided by tumor genotype, p53 status, and the inflammatory signature of the microenvironment. Structural insights into the oligomerization interface provide a concrete starting point for the development of small-molecule modulators that could tip this balance in either direction.

What emerges from this synthesis is a portrait of cell death as a finely engineered process whose final mechanical step carries as much biological meaning as the genetic programs that trigger it. NINJ1, once a footnote in the cell death literature, now stands at the intersection of structural biology, immunology, and oncology, a protein that decides how loudly a dying cell announces its demise and whether that announcement heals or harms. As clinical trials of cell death modulators advance and structural biology continues to refine our understanding of the NINJ1 filament, the coming years may determine whether this membrane rupture executor can be harnessed as a versatile tool, quieting catastrophic inflammation on one hand and igniting anti-tumor immunity on the other. For a molecule that works by tearing membranes apart, NINJ1 is proving remarkably adept at knitting together previously separate fields of biomedical research.

Subject of Research: The role of the NINJ1 protein in plasma membrane rupture during regulated cell death and its dual functions in cancer progression

Article Title: NINJ1 in regulated cell death and cancer: a plasma membrane rupture executor with dual roles in tumor progression

Article References: Zhou, J., Li, M., Tan, S., & Tan, S. (2026). NINJ1 in regulated cell death and cancer: a plasma membrane rupture executor with dual roles in tumor progression. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06592-9

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06592-9

Keywords: NINJ1, plasma membrane rupture, regulated cell death, pyroptosis, necroptosis, ferroptosis, PANoptosis, immunogenic cell death, tumor microenvironment, p53–NINJ1–xCT axis, cancer therapy, inflammation

The clinical context makes the urgency clear. For decades, randomized trials of adjuvant chemoradiotherapy after pancreatic surgery, including landmark studies from the European Study Group for Pancreatic Cancer and the RTOG, have produced conflicting or marginal survival benefits. More recent trials such as PREOPANC and PREOPANC-2 have tested neoadjuvant chemoradiotherapy against chemotherapy-first strategies, with results that have done little to resolve the controversy. Meanwhile, the LAP07 and CONKO-007 trials failed to demonstrate clear survival advantages for adding radiation in locally advanced disease. The authors argue that these disappointments reflect a deeper problem: conventional radiotherapy was designed and optimized purely as a cytotoxic tool, with little attention to how radiation doses, fractionation schedules, target volumes and delivery techniques shape the immune microenvironment of the tumor.

The immunological rationale for combining radiation with immunotherapy rests on a growing body of preclinical evidence. Radiation can kill cancer cells in ways that release tumor antigens and danger signals, triggering what is known as immunogenic cell death. This process can recruit and activate dendritic cells, which carry tumor antigens to lymph nodes and prime CD8-positive T cells capable of recognizing and destroying malignant cells throughout the body, including at sites never directly irradiated. This systemic effect, called the abscopal response, has long been considered rare and unpredictable. But work from multiple laboratories, including studies of the DNA exonuclease Trex1 and the cGAS-STING DNA sensing pathway, has revealed that whether radiation stimulates or suppresses immunity depends exquisitely on dose, fractionation and timing, parameters that clinicians have historically chosen without immunological consideration.

Pancreatic cancer presents unique obstacles to this strategy. The disease is characterized by an exceptionally immunosuppressive tumor microenvironment, dominated by dense stromal desmoplasia, cancer-associated fibroblasts, immunosuppressive macrophages, myeloid-derived suppressor cells and regulatory T cells that collectively exclude or exhaust cytotoxic lymphocytes. The tumor’s low mutation burden limits the availability of neoantigens that could be recognized by the immune system. Landmark clinical trials of checkpoint inhibitors in pancreatic cancer, including ipilimumab as a single agent, the durvalumab and tremelimumab combination, and the PRINCE and CCTG PA.7 studies of immunotherapy added to chemotherapy, have all failed to deliver meaningful survival improvements outside the rare subset of patients with microsatellite instability. The authors stress that this track record does not mean immunotherapy is hopeless in pancreatic cancer, but rather that checkpoint blockade alone cannot overcome the disease’s profound immune barriers without complementary interventions.

Here, radiotherapy could serve as the missing catalyst. Preclinical studies in pancreatic cancer models have shown that radiation can increase tumor infiltration by effector T cells, polarize tumor-associated macrophages toward pro-inflammatory phenotypes, and enhance the efficacy of checkpoint blockade, CD40 agonist antibodies, and even CAR T cell therapies directed against targets such as mesothelin and claudin 18.2. Radiation conditioning has been shown to mitigate antigen escape in CAR T cell approaches, and low-dose irradiation can reprogram macrophage differentiation in ways that support T cell function. These findings suggest that radiation, delivered with the right parameters, could transform a cold, immune-excluded pancreatic tumor into one that is susceptible to systemic immunotherapy.

Crucially, the authors emphasize that the details of radiation delivery matter enormously. Preclinical work has demonstrated that ablative stereotactic doses, conventional fractionation, and hypofractionated schedules each produce distinct immunological fingerprints. High single doses may trigger the Trex1-mediated degradation of cytosolic DNA, actually blunting the interferon response that drives antitumor immunity, whereas certain fractionated schedules preserve and amplify cGAS-STING signaling. The sequencing of immunotherapy relative to radiation also matters: studies have shown that the timing of PD-1 blockade relative to tumor irradiation determines whether abscopal responses are induced. Emerging technologies such as magnetic resonance-guided adaptive radiotherapy, FLASH ultrahigh dose-rate irradiation, pulsed low-dose-rate techniques, proton and carbon ion therapy, and spatially fractionated approaches offer clinicians an expanding toolkit for sculpting the immunological consequences of each radiation session.

The article also highlights next-generation immunotherapeutic partners that may prove more suitable than conventional checkpoint inhibitors for combination with radiation in pancreatic cancer. Personalized mRNA neoantigen vaccines have already demonstrated the ability to expand tumor-specific T cells in resected pancreatic cancer patients, and mutational KRAS-targeted vaccine strategies combined with dual checkpoint blockade have shown encouraging results in early trials. Agonist CD40 antibodies capable of activating antigen-presenting cells, Toll-like receptor agonists, IL-15 and IL-2 pathway modulators, STING agonists, adenosine pathway blockers such as CD73 and A2A receptor inhibitors, and stromal reprogramming agents including focal adhesion kinase inhibitors and TGF-beta antagonists all represent rational partners. Novel platforms including tumor-targeted cytokines, radiopharmaceuticals, boron neutron capture therapy, and radiotherapy-activated prodrugs that release immune agonists only within irradiated tissue further expand the possibilities for precisely timed, spatially controlled immune activation.

The authors also draw attention to an often-overlooked variable: the tumor-draining lymph nodes and circulating lymphocytes. Elective nodal irradiation, a mainstay of conventional radiotherapy field design, has been shown in preclinical studies to attenuate the combinatorial efficacy of stereotactic radiation and immunotherapy by depleting the very lymphoid structures needed to prime systemic immunity. Radiation-induced lymphopenia, a common toxicity of large-field abdominal irradiation, may undermine the systemic immune benefits of radioimmunotherapy. Newer approaches that minimize exposure of lymphoid organs, preserve lymphatic drainage, and exploit artificial intelligence-guided treatment planning to spare circulating lymphocytes may be essential for unlocking the full potential of combined regimens. Proton therapy, with its reduced exit dose, offers a physically grounded strategy for reducing lymphocyte exposure compared with photon techniques.

Looking forward, the authors propose a decision map for clinical development that incorporates biomarker-guided patient selection, adaptive trial designs, and rational sequencing of optimized radiation backbones with selected immunotherapeutic agents. Advances in radiomics, genomic models of radiation sensitivity, liquid biopsy, and imaging technologies such as FAPI-PET may allow clinicians to identify which patients and which tumors are most likely to respond to specific radioimmunotherapy combinations. Biomarkers of immune activation, including circulating tumor DNA kinetics, immune cell signatures, and imaging features of the tumor microenvironment, could enable real-time adaptation of treatment strategies. The authors argue that progress will depend on moving beyond empirical combinations toward mechanistically informed designs in which every element of the radiation prescription, from dose and fractionation to target volume and delivery modality, is chosen deliberately for its immunological consequences.

Ultimately, the perspective reframes localized pancreatic cancer as a disease that may finally yield to a truly integrated therapeutic approach. Rather than viewing radiotherapy and immunotherapy as competing strategies with individually disappointing track records, the authors make a compelling case that the two modalities, when co-optimized at the level of physics, biology and clinical trial design, could simultaneously improve local tumor control and suppress the micrometastatic disease that drives most deaths from this cancer. With pancreatic cancer projected to become the second leading cause of cancer-related death in the United States by 2040, and with current treatment paradigms delivering only marginal gains, the stakes of getting this combination right could not be higher. The blueprint laid out by Colin and colleagues offers the field a rigorous, immunologically grounded path forward, one that transforms radiation from a purely destructive force into an active partner in mobilizing the patient’s immune system against one of medicine’s most lethal malignancies.

Subject of Research: Combining optimized radiotherapy with next-generation immunotherapy for localized pancreatic ductal adenocarcinoma.

Article Title: Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer

Article References: Colin, G., Streel, S., Deutsch, E., Galluzzi, L., & Foidart, P. (2026). Challenges and opportunities in combining radiotherapy and immunotherapy for localized pancreatic cancer. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-026-01250-4

Image Credits: AI Generated

DOI: 10.1038/s41575-026-01250-4

Keywords: pancreatic cancer, radiotherapy, immunotherapy, immune checkpoint blockade, localized pancreatic ductal adenocarcinoma, tumor microenvironment, abscopal effect, immunogenic cell death, stereotactic body radiation therapy, FLASH radiotherapy, biomarker-guided trials, stromal reprogramming

The research was led by a multidisciplinary team at Guangdong Provincial People’s Hospital affiliated with Southern Medical University, together with collaborators at several other Chinese institutions. The investigators combined quantitative proteomics, a technique that measures the full complement of proteins in cells, with N4-acetylcytidine RNA immunoprecipitation sequencing, or acRIP-seq, which maps a specific chemical tag deposited onto messenger RNA molecules. They also drew on CRISPR-based dependency screens, which systematically disable genes one by one to reveal which ones cancer cells cannot live without. This triple lens allowed them to sift through the molecular chaos of radiation-resistant glioblastoma cells and pinpoint NAT10 as a standout culprit whose activity correlates with both treatment failure and poor patient survival.

NAT10 is what scientists call a writer of the epitranscriptome, the layer of chemical modifications that adorn RNA molecules without altering the underlying genetic sequence. Specifically, NAT10 installs a modification called N4-acetylcytidine, abbreviated ac4C, onto messenger RNAs. These chemical tags act like molecular Post-it notes, influencing how stable an RNA molecule is and how efficiently it is translated into protein. While aberrant RNA modifications have increasingly been implicated in cancer progression, the specific epitranscriptomic vulnerabilities that allow glioblastoma to withstand radiation had remained largely unexplored. The new study fills that gap with an unusually detailed mechanistic account.

At the heart of the discovery lies a gene called SLC7A11, which encodes a cellular transporter responsible for importing cystine, a building block of the antioxidant glutathione. Using acRIP-seq, the researchers found that NAT10 deposits ac4C marks directly onto SLC7A11 messenger RNA. These marks stabilize the transcript and enhance its translation into protein, effectively turning up the volume on the cell’s antioxidant machinery. The consequences are profound for a tumor facing radiation. Ionizing radiation kills cells in part by generating reactive oxygen species that damage DNA and membranes. A cell brimming with glutathione and the protective enzyme glutathione peroxidase 4, or GPX4, is well armored against this oxidative barrage, and elevated SLC7A11 provides exactly that armor.

The study goes further by connecting this antioxidant shield to a form of cell death that has captivated cancer biologists in recent years: ferroptosis. Ferroptosis is an iron-dependent demise driven by the accumulation of lipid peroxides in cellular membranes, and it can be unleashed when antioxidant defenses, particularly the glutathione-GPX4 axis, falter. The researchers demonstrated that glioblastoma cells with high NAT10 activity evade radiation-induced ferroptosis by keeping SLC7A11 levels high. When the team used a catalytically inactive mutant of NAT10, designated NAT10-G641E, they confirmed that the enzyme’s acetylation activity, not some unrelated function, was responsible for the effect. RNA stability assays and polysome profiling, which measure how actively messenger RNAs are being translated, reinforced the causal chain from NAT10, through ac4C on SLC7A11 mRNA, to antioxidant capacity and ferroptosis resistance.

Perhaps the most striking finding is that interfering with NAT10 does more than simply make tumor cells easier to kill. When glioblastoma cells lose their NAT10-driven antioxidant defenses and undergo ferroptosis in response to radiation, they die in a way that rings alarm bells for the immune system. This phenomenon, known as immunogenic cell death, involves the release of damage-associated molecular patterns such as calreticulin, adenosine triphosphate, and high mobility group box 1, which promote the maturation of dendritic cells and activate cytotoxic CD8-positive T cells. In orthotopic mouse models, where tumors are grown inside the brain, NAT10 inhibition triggered what the authors describe as a cold-to-hot transformation of the tumor microenvironment, converting an immunosuppressive, T-cell-poor landscape into one teeming with tumor-fighting immune cells.

This immunological dimension matters because glioblastoma has been notoriously refractory to immunotherapy. Its brain location, the blood-brain barrier, and a profoundly immunosuppressive microenvironment rich in suppressive myeloid cells have conspired to defeat most attempts to harness the immune system against it. A therapy that simultaneously lowers the biochemical threshold for radiation killing and recruits an immune response offers a two-pronged attack that could be more potent than either approach alone. The findings suggest that ferroptosis, long studied primarily as a cell-intrinsic vulnerability, can serve as a bridge between radiotherapy and anticancer immunity in the brain.

Translating this biology into a therapy required a practical inhibitor of NAT10. Existing NAT10 inhibitors carry toxicity concerns that limit their appeal, so the research team turned to computational drug repurposing, screening approved drugs for the ability to disrupt the NAT10-ac4C-SLC7A11 axis. Their search converged on pemetrexed, an antifolate chemotherapy already in clinical use for other cancers. In their experiments, pemetrexed suppressed NAT10 activity, destabilized SLC7A11 messenger RNA, and stripped glioblastoma cells of their glutathione supply. When combined with radiotherapy in mouse models, pemetrexed produced profound synergistic survival benefits, validating the repurposing strategy and offering a potentially safer path to the clinic than purpose-built NAT10 inhibitors.

The study also carries prognostic weight for patients. By analyzing patient cohorts, the researchers showed that NAT10 expression correlates with poor overall survival and poor progression-free survival in glioblastoma, positioning the enzyme as both a biomarker of aggressive disease and a therapeutic target. The work received ethics approval from the review board of Guangdong Provincial People’s Hospital and the Animal Ethics Committee of Nanfang Hospital, and it was funded by the National Natural Science Foundation of China along with provincial and municipal science foundations in Guangdong and Guangzhou.

For a cancer that has seen precious few therapeutic advances in decades, the convergence of RNA modification biology, ferroptosis, and immunology in a single actionable axis is notable. The results imply that doctors might one day stratify glioblastoma patients by NAT10 activity, administer pemetrexed alongside standard radiotherapy to collapse the tumors’ antioxidant defenses, and thereby convert a silently resistant tumor into an immunologically visible one. Considerable work remains before such a regimen reaches patients, including clinical trials to establish dosing, safety, and efficacy in humans with brain tumors. But the study provides a rigorous mechanistic foundation for that effort, demonstrating with molecular precision how a single RNA writer enzyme can govern whether radiation becomes a lethal blow to a tumor or merely a wound that heals. In the difficult landscape of glioblastoma research, findings of this clarity are rare, and they renew hope that even the most radiation-resistant cancers can be made vulnerable through a deeper understanding of their chemistry.

Subject of Research: NAT10-mediated RNA acetylation driving glioblastoma radioresistance through suppression of immunogenic ferroptosis

Article Title: N-acetyltransferase 10 promotes glioblastoma radioresistance by suppressing immunogenic ferroptosis through N4-acetylcytidine of SLC7A11 mRNA

Article References: Hu, S., Cheng, J., Liu, Y., Chen, C., Qiu, R., Liu, Y., Zhang, Q., Xie, Y., Wan, B., Tan, P., Xie, D., Lei, Y., Luo, H., Feng, W., Deng, Y., Hua, X., Ren, C., & Du, S. (2026). N-acetyltransferase 10 promotes glioblastoma radioresistance by suppressing immunogenic ferroptosis through N4-acetylcytidine of SLC7A11 mRNA. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03822-3

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03822-3

Keywords: glioblastoma, NAT10, N4-acetylcytidine, radioresistance, ferroptosis, SLC7A11, pemetrexed, immunogenic cell death, epitranscriptomics, radiotherapy, tumor microenvironment, drug repurposing

The authors ground their argument in a fundamental limitation shared by immune checkpoint inhibitors and early-generation oncolytic viruses alike: both depend on pre-existing tumor-specific T cells to work. Checkpoint blockade releases the brakes on T cells that already recognize cancer, but it has little capacity to generate new tumor-reactive clones de novo. Similarly, first-generation OVs were designed primarily to replicate in and destroy tumor cells, releasing antigens in the hope that an antitumor response would follow. If a patient’s immune system has not already been sensitized to their cancer, the ceiling on efficacy is set by the existing T cell repertoire, an immunological constraint that clinical experience has repeatedly confirmed. Resistance rates for checkpoint inhibitors across tumor types remain substantial, and even approved OVs have produced durable responses mainly in a subset of patients.

The central conceptual advance proposed in the Perspective is that next-generation OVs overcome this ceiling by functioning as antigen-agnostic, in situ cancer vaccines. When an oncolytic virus infects a tumor, it triggers immunogenic cell death, a form of tumor destruction that releases not just one or two chosen antigens but potentially the full cancer proteome, all under adjuvant conditions created by pathogen-associated and damage-associated molecular patterns. Dendritic cells patrolling the inflamed tumor microenvironment engulf this debris and migrate to draining lymph nodes, where they present the entire antigenic spectrum of that patient’s cancer, including private neoantigens arising from mutations unique to the tumor. This process can broaden the T cell clonotype repertoire, effectively priming brand-new tumor-specific T cells rather than merely reactivating exhausted ones. In essence, each treated tumor becomes its own personalized vaccine factory, without needing to sequence a patient’s genome or manufacture an individualized product.

The authors organize the path forward around four pillars. The first is intratumoural vaccination as immunological ignition. They cite early clinical data demonstrating T cell clonotype broadening, regression of uninjected, so-called abscopal lesions, and survival benefit in patients whose disease had already failed checkpoint inhibitor therapy. These signals matter because abscopal responses, long considered rare curiosities of radiotherapy and immunotherapy, provide direct evidence that a locally delivered virus can reprogram immunity systemically. The second pillar is optimized, payload-driven immune priming. Modern OVs are increasingly engineered to carry transgenes encoding cytokines such as granulocyte-macrophage colony-stimulating factor, interleukin-12 and interleukin-15, or antibodies and nanobodies that block checkpoint pathways or hyperactivate antigen-presenting cells. The design goal is to convert the natural viral danger signals into a maximally productive priming event for dendritic cells and, through them, for naive T cells.

The third pillar addresses a quieter crisis in the field: how efficacy is measured. Standard RECIST criteria, which track the shrinkage of injected and measurable lesions, can systematically underestimate the delayed, nonlinear kinetics of immune-mediated tumor control. The authors call for revised evaluation frameworks incorporating immune-specific response criteria such as iRECIST, attention to durable response rates, and novel biological correlates such as circulating tumor DNA dynamics and T cell receptor repertoire diversification. Evidence already suggests that for some immunotherapies, including oncolytic agents, apparent stable disease can conceal a durable immune equilibrium that translates into extended overall survival even without dramatic radiographic regression. Regulatory acceptance of endpoints that capture these patterns will be essential if next-generation OVs are to reach patients.

The fourth and most ambitious pillar is the positioning of OVs as the foundational immuno-oncology platform, formalized in what the authors call the triple-A framework. Productive antitumor immunity requires three sequential gates: admission of T cells into the tumor, their availability in sufficient numbers with appropriate specificity, and their activation to effector function. Most therapeutic modalities satisfy only one or two of these conditions. Checkpoint inhibitors excel at activation but assume T cells are already present and tumor-specific. Adoptive cell therapies and bispecific T cell engagers supply availability and activation but struggle with physical admission into immunosuppressed, poorly vascularized tumor stroma. Payload-engineered next-generation OVs, the authors argue, are unique in satisfying all three prerequisites simultaneously: viral infection remodels the microenvironment to admit T cells, in situ vaccination generates and expands tumor-specific clones to ensure availability, and inflammatory danger signals plus engineered payloads drive activation.

The clinical landscape they survey is evolving rapidly. Talimogene laherparepvec, the first approved oncolytic virus in the United States, established proof of principle in melanoma, and combination trials with pembrolizumab and ipilimumab have tested whether viral priming can amplify checkpoint blockade. A strategy the authors describe as OV-prime, ICI-amplify is supported by trial data showing that vaccinating the immune system with a virus first and then removing inhibitory brakes with an antibody can yield benefit even in patients refractory to checkpoints alone. Newer agents illustrate the payload engineering trend: RP1, an oncolytic herpesvirus expressing GM-CSF and a fusogenic protein, has shown activity with nivolumab in anti-PD-1-failed melanoma and recently gained support from a US Food and Drug Administration advisory committee. In China, VG161, a multi-armoured oncolytic herpesvirus carrying multiple immunomodulatory transgenes, has demonstrated survival benefits in refractory hepatocellular carcinoma, while T3011, an oncolytic herpesvirus expressing both interleukin-12 and a PD-1 antibody, has entered first-in-human testing in advanced solid tumors.

Delivery logistics remain a genuine constraint that the authors confront directly. Most OVs are administered by intratumoral injection, which is straightforward for accessible cutaneous lesions but demanding for deep visceral metastases, although ultrasound-guided techniques are expanding the reachable set. Intravenous delivery, which would extend the approach to diffuse disease, is hampered by neutralizing antibodies, hepatic clearance and off-target sequestration, prompting engineering solutions ranging from cell carriage by mesenchymal stem cells and immune cells to polymer coating and tumor-specific promoter control of viral replication. Pre-existing antiviral immunity, once viewed purely as a barrier, may in some contexts enhance rather than diminish therapeutic efficacy by amplifying inflammatory recruitment to infected tumors. None of these obstacles is trivial, but the Perspective treats them as engineering problems rather than conceptual dead ends.

The broader significance of the argument lies in its reframing of therapeutic sequencing. If oncolytic viruses are truly systemic immune-reprogramming platforms, then the optimal role for an OV in a treatment regimen may be as the priming event, the ignition that creates the tumor-specific T cell pool, with checkpoint inhibitors, bispecifics or adoptive cells deployed afterwards to amplify and sustain the response. The authors acknowledge competing interests that come with their positions in oncolytic virotherapy companies, and the piece is explicitly a Perspective rather than a definitive clinical mandate. Still, the case they assemble, spanning mechanistic immunology, evolving trial data and a coherent framework for combination design, makes a credible argument that the field’s future lies not in making cold tumors hot, but in teaching the immune system, one infected tumor at a time, to recognize cancers it had never seen.

Historical context reinforces the authors’ argument that the field has been converging on this reframing for decades. The conceptual roots of oncolytic virotherapy stretch back more than a century to anecdotal reports of tumor regression after natural viral infections, but the modern era began in the early 1990s when Robert Martuza’s group described a genetically engineered herpes simplex virus mutant that could replicate in and destroy glioma cells. Landmark studies in the late 1990s and early 2000s established the tumor-selective logic of the field, exploiting activated ras signaling pathways, p53-deficient tumor cells, and defective interferon responses that characterize many cancers. Notably, the in situ vaccination concept itself was articulated in preclinical work as early as 1998, when replication-competent herpesviruses engineered to carry interleukin-12 were shown to induce local and systemic antitumor immunity, suggesting the current Perspective formalizes ideas whose time has finally arrived with enabling payload technology.

Safety data also support the platform’s maturation. Systematic reviews and meta-analyses of oncolytic virotherapy across malignancies have generally found favorable tolerability profiles, with most adverse events consisting of transient fever, injection-site reactions, and flu-like symptoms rather than the immune-related toxicities that complicate checkpoint blockade. This tolerability is clinically meaningful because it permits rational combination with other immunotherapies without prohibitive overlapping toxicity, a persistent challenge in immuno-oncology. At the same time, the empirical analysis of checkpoint inhibitor eligibility and response rates cited by the authors underscores the scale of unmet need: only a minority of patients who receive checkpoint inhibitors derive durable benefit, leaving a large population for whom antigen-agnostic priming strategies could be decisive. Whether the four-pillar framework translates into regulatory endorsements and standardized endpoints will likely determine how quickly next-generation oncolytic viruses move from promising biology to established cornerstone of cancer care.

Subject of Research: Next-generation oncolytic virotherapy as antigen-agnostic in situ cancer vaccination and a foundational immuno-oncology platform

Article Title: Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology

Article References: Jia, W., Zhao, R., Kaufman, H. L., & Martuza, R. L. (2026). Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-026-01198-z

Image Credits: AI Generated

DOI: 10.1038/s41571-026-01198-z

Keywords: oncolytic virotherapy, immuno-oncology, immune checkpoint inhibitors, in situ cancer vaccination, tumor-specific T cells, immunogenic cell death, abscopal response, neoantigens, talimogene laherparepvec, dendritic cells, triple-A framework, cancer immunotherapy

The strategy addresses a central challenge in cancer immunotherapy. Many treatments can kill tumour cells, but cell death does not automatically produce effective antitumour immunity. For immune cells to recognize and attack cancer, dying tumour cells must release or display molecular signals that stimulate antigen-presenting cells. These signals, often described as damage-associated molecular patterns, can promote the uptake of tumour material by dendritic cells and help initiate T-cell responses. The researchers sought to design a form of cell death that would not simply eliminate tumour cells, but would also make their destruction immunologically productive.

The key component, aMP₍C16₎-CA₅₀, is a synthetic acid-responsive membranolytic peptide. Peptides of this class can disrupt lipid membranes by interacting with their surfaces and inserting into the bilayer, potentially forming defects or pores that compromise membrane integrity. What distinguishes this molecule is its hierarchical response to acidity. Tumour tissues commonly possess a mildly acidic extracellular environment, while lysosomes inside cells are substantially more acidic. The peptide was designed to respond to these changing pH conditions in stages, allowing its activity to be controlled by both location and time.

This sequence begins as the peptide encounters the acidic environment surrounding tumour cells and subsequently enters the cells. Once transported into lysosomes, where the pH is lower, the molecule becomes more strongly activated and damages lysosomal membranes. Lysosomal rupture releases enzymes and other contents into the cytoplasm, generating intense intracellular stress and activating inflammatory pathways. The plasma membrane then ruptures later, rather than simultaneously. According to the study, this delay is crucial: it gives the tumour cell time to develop an inflammatory transcriptional response before its final collapse and may improve the quality of the immune signals released during lysis.

The researchers describe this programmed process as immunogenic membranolytic cell death, or mLCD. Its defining feature is therefore not merely membrane destruction, but the spatiotemporal coordination of membrane damage. The order in which the lysosomal and plasma membranes fail can influence how a dying cell communicates with the immune system. Early lysosomal disruption may activate intracellular danger pathways, while delayed plasma-membrane rupture releases tumour-associated antigens and inflammatory mediators into the surrounding tissue. This combination could provide immune cells with both the warning signals and the tumour-specific material needed to mount a coordinated response.

Laboratory experiments indicated that aMP₍C16₎-CA₅₀ activated inflammatory gene-expression programs in tumour cells. These programs increased the ability of tumour-cell material to stimulate antigen presentation by dendritic cells. Antigen presentation is a critical bridge between innate and adaptive immunity: dendritic cells process proteins from damaged cells, load fragments onto major histocompatibility complex class I molecules and display them to T cells. When the displayed fragments originate from tumour cells, this interaction can help activate cytotoxic T lymphocytes capable of recognizing and killing cancer cells elsewhere in the body.

The findings also connect the peptide’s membrane-disrupting kinetics to the performance of immune checkpoint blockade. Checkpoint inhibitors, including therapies aimed at pathways such as PD-1, PD-L1 or CTLA-4, can restore T-cell activity, but they often work best when a tumour has already generated a strong immune response. By increasing antigen release and inflammatory signalling, the programmed mLCD approach may help convert immunologically quiet tumours into more responsive ones. In the reported experiments, aMP₍C16₎-CA₅₀ substantially enhanced the antitumour effects of immune checkpoint blockade, suggesting that the peptide could function as an immune-priming treatment rather than as a stand-alone cytotoxic agent.

The study further reports that systemic administration of the peptide was well tolerated in mice, an important consideration for any membrane-lytic therapy. Molecules that disrupt membranes can raise concerns about damage to healthy tissues, red blood cells or vital organs. The researchers’ pH-dependent design is intended to concentrate activity in acidic tumour environments and intracellular lysosomes, potentially limiting unwanted effects in normal tissues. However, the safety results remain preclinical. The distribution, metabolism, immune effects and toxicity of the peptide will need to be examined in more advanced animal studies before its relevance to human treatment can be determined.

The work illustrates a broader shift in cancer-drug design: instead of treating cell death as a single endpoint, researchers are attempting to program how, where and when a tumour cell dies. By manipulating membrane biology with a synthetic peptide, the team created a death process that links physical destruction to inflammatory gene activation and adaptive immune stimulation. If the concept can be translated safely beyond mice, pH-responsive membranolytic peptides could become a versatile platform for improving immunotherapy, particularly in tumours that currently resist checkpoint inhibitors. For now, the study provides a striking example of how precisely timed cellular damage can transform tumour-cell death into an active signal for the immune system.

Subject of Research:
A pH-responsive synthetic membranolytic peptide designed to induce immunogenic membranolytic cell death in tumour cells and enhance immune checkpoint blockade therapy.

Article Title:
Membranolytic peptide programs immunogenic cell death for cancer therapy

Article References:
Yuan, Y., Liang, L., Li, J. et al. “Membranolytic peptide programs immunogenic cell death for cancer therapy.” Nature (2026). https://doi.org/10.1038/s41586-026-10899-5

Image Credits:
AI Generated

DOI:
https://doi.org/10.1038/s41586-026-10899-5

Keywords:
Immunogenic cell death, membranolytic peptide, cancer immunotherapy, pH-responsive therapy, lysosomal membrane rupture, plasma membrane rupture, dendritic cells, T-cell activation, immune checkpoint blockade, tumour microenvironment